Cargando…

The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study

Severe obesity is a strong risk factor for non-alcoholic fatty liver disease (NAFLD). Roux-en-Y gastric bypass (RYGB) surgery effectively induces weight loss, but few studies have described the long-term effects of RYGB on NAFLD-related fibrosis. Data from 220 patients with severe obesity operated b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sandvik, Elfrid Christine Smith, Aasarød, Kristin Matre, Johnsen, Gjermund, Hoff, Dag Arne Lihaug, Kulseng, Bård, Hyldmo, Åsne Ask, Græslie, Hallvard, Nymo, Siren, Sandvik, Jorunn, Fossmark, Reidar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409952/
https://www.ncbi.nlm.nih.gov/pubmed/36013149
http://dx.doi.org/10.3390/jcm11164910
_version_ 1784774976245596160
author Sandvik, Elfrid Christine Smith
Aasarød, Kristin Matre
Johnsen, Gjermund
Hoff, Dag Arne Lihaug
Kulseng, Bård
Hyldmo, Åsne Ask
Græslie, Hallvard
Nymo, Siren
Sandvik, Jorunn
Fossmark, Reidar
author_facet Sandvik, Elfrid Christine Smith
Aasarød, Kristin Matre
Johnsen, Gjermund
Hoff, Dag Arne Lihaug
Kulseng, Bård
Hyldmo, Åsne Ask
Græslie, Hallvard
Nymo, Siren
Sandvik, Jorunn
Fossmark, Reidar
author_sort Sandvik, Elfrid Christine Smith
collection PubMed
description Severe obesity is a strong risk factor for non-alcoholic fatty liver disease (NAFLD). Roux-en-Y gastric bypass (RYGB) surgery effectively induces weight loss, but few studies have described the long-term effects of RYGB on NAFLD-related fibrosis. Data from 220 patients with severe obesity operated by RYGB in Central Norway were analysed. Variables incorporated in NAFLD Fibrosis Score (NFS), Fibrosis-4 (FIB-4) index and anthropometric data were collected before surgery and a mean of 11.6 years postoperatively. FIB-4 > 1.3 or NFS > 0.675 were used as cut-off values for advanced fibrosis. Proportions with advanced fibrosis decreased from 24% to 14% assessed by FIB-4 and from 8.6% to 2.3% using NFS, with resolution rates of advanced fibrosis of 42% and 73%, respectively. The shift towards lower fibrosis categories was significant (NFS p < 0.0001; FIB-4 p = 0.002). NFS decreased from −1.32 (IQR −2.33–−0.39) to −1.71 (IQR −2.49–−0.95, p < 0.001) 11.6 years after surgery, whereas FIB-4 did not change: 0.81 (IQR 0.59–1.25) to 0.89 (IQR 0.69–1.16, p = 0.556). There were weak correlations between change in fibrosis scores and weight loss. In conclusion, the majority of patients with advanced fibrosis at baseline had improvement after 11.6 years. Factors associated with reduction in fibrosis were not identified.
format Online
Article
Text
id pubmed-9409952
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94099522022-08-26 The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study Sandvik, Elfrid Christine Smith Aasarød, Kristin Matre Johnsen, Gjermund Hoff, Dag Arne Lihaug Kulseng, Bård Hyldmo, Åsne Ask Græslie, Hallvard Nymo, Siren Sandvik, Jorunn Fossmark, Reidar J Clin Med Article Severe obesity is a strong risk factor for non-alcoholic fatty liver disease (NAFLD). Roux-en-Y gastric bypass (RYGB) surgery effectively induces weight loss, but few studies have described the long-term effects of RYGB on NAFLD-related fibrosis. Data from 220 patients with severe obesity operated by RYGB in Central Norway were analysed. Variables incorporated in NAFLD Fibrosis Score (NFS), Fibrosis-4 (FIB-4) index and anthropometric data were collected before surgery and a mean of 11.6 years postoperatively. FIB-4 > 1.3 or NFS > 0.675 were used as cut-off values for advanced fibrosis. Proportions with advanced fibrosis decreased from 24% to 14% assessed by FIB-4 and from 8.6% to 2.3% using NFS, with resolution rates of advanced fibrosis of 42% and 73%, respectively. The shift towards lower fibrosis categories was significant (NFS p < 0.0001; FIB-4 p = 0.002). NFS decreased from −1.32 (IQR −2.33–−0.39) to −1.71 (IQR −2.49–−0.95, p < 0.001) 11.6 years after surgery, whereas FIB-4 did not change: 0.81 (IQR 0.59–1.25) to 0.89 (IQR 0.69–1.16, p = 0.556). There were weak correlations between change in fibrosis scores and weight loss. In conclusion, the majority of patients with advanced fibrosis at baseline had improvement after 11.6 years. Factors associated with reduction in fibrosis were not identified. MDPI 2022-08-21 /pmc/articles/PMC9409952/ /pubmed/36013149 http://dx.doi.org/10.3390/jcm11164910 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sandvik, Elfrid Christine Smith
Aasarød, Kristin Matre
Johnsen, Gjermund
Hoff, Dag Arne Lihaug
Kulseng, Bård
Hyldmo, Åsne Ask
Græslie, Hallvard
Nymo, Siren
Sandvik, Jorunn
Fossmark, Reidar
The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study
title The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study
title_full The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study
title_fullStr The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study
title_full_unstemmed The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study
title_short The Effect of Roux-en-Y Gastric Bypass on Non-Alcoholic Fatty Liver Disease Fibrosis Assessed by FIB-4 and NFS Scores—An 11.6-Year Follow-Up Study
title_sort effect of roux-en-y gastric bypass on non-alcoholic fatty liver disease fibrosis assessed by fib-4 and nfs scores—an 11.6-year follow-up study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409952/
https://www.ncbi.nlm.nih.gov/pubmed/36013149
http://dx.doi.org/10.3390/jcm11164910
work_keys_str_mv AT sandvikelfridchristinesmith theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT aasarødkristinmatre theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT johnsengjermund theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT hoffdagarnelihaug theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT kulsengbard theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT hyldmoasneask theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT græsliehallvard theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT nymosiren theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT sandvikjorunn theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT fossmarkreidar theeffectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT sandvikelfridchristinesmith effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT aasarødkristinmatre effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT johnsengjermund effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT hoffdagarnelihaug effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT kulsengbard effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT hyldmoasneask effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT græsliehallvard effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT nymosiren effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT sandvikjorunn effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy
AT fossmarkreidar effectofrouxenygastricbypassonnonalcoholicfattyliverdiseasefibrosisassessedbyfib4andnfsscoresan116yearfollowupstudy